Abstract:Michael H Storandt, 1 Zhaohui Jin, 2 Amit Mahipal 3 1 Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2 Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; 3 Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA Correspondence: Amit Mahipal, University Hospitals Seidman Cancer Center, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH, 44106, USA, Tel +1 216-844-3951, Email Advanced biliary tract cancers (BTCs) have historically been managed with chemotherapy but, in recent years, this treatment paradigm has begun to shift with the introduction of immune checkpoint inhibitors in addition to standard of care chemotherapy. The tumor microenvironment of BTC may be enriched with regulatory T lymphocytes and immune checkpoint expression in some patients. Durvalumab, an anti-programmed death ligand-1 (PD-L1) antibody, in combination with gemcitabine and cisplatin, has now received United States Food and Drug Administration approval for treatment of advanced BTC. Regulatory approval was based on the Phase III, randomized TOPAZ-1 trial that demonstrated survival benefit with addition of durvalumab to gemcitabine plus cisplatin compared to chemotherapy alone. The combination of chemotherapy and immunotherapy was well tolerated, and a subset of patients were able to achieve a durable response, with a 2-year overall survival rate of 23.6%. However, limitations remain in identifying which patients are most likely to benefit from immune checkpoint inhibition. Future study should aim to identify biomarkers predictive of substantial benefit, as well as the role of immune checkpoint inhibition in combination with targeted therapies and radiotherapy in the management of advanced BTC. Keywords: durvalumab, immunotherapy, cholangiocarcinoma, bile duct cancers Biliary tract cancers (BTCs), arising from the biliary epithelium, include intra- and extra-hepatic cholangiocarcinoma (CCA), gallbladder carcinoma (GC), and ampullary carcinoma (AC). BTC has an incidence of 2.32 cases per 100,000 in the United States (US) and, globally, the highest incidence is found in Asia and South America. 1 In the US, the most common subtype is intrahepatic CCA, with an estimated incidence of approximately 1.5 cases per 100,000, followed by GC, extrahepatic CCA, and lastly, AC. 2 The incidence of BTCs is projected to increase in the coming years, with the largest contribution by intrahepatic CCA. 3,4 Historically, treatment of advanced BTC consisted of gemcitabine plus cisplatin based on ABC-02, which randomized patients with advanced or metastatic BTC to gemcitabine with or without cisplatin and demonstrated an improvement in median overall survival (mOS) with the combination regimen compared to single agent gemcitabine [11.7 vs 8.1 months, hazard ratio (HR) = 0.64, 95% confidence interval (CI) = 0.52–0.80, p <0.001]. 5 Following this trial, subsequent studies failed to demonstrate the superiority of alternative regimens. SWOG 1815 failed to show a survival benefit with the addition of nab-paclitaxel to gemcitabine plus cisplatin. 6 PRODIGE 38 AMEBICA, which randomized patients to FOLFIRINOX or gemcitabine plus cisplatin, failed to meet its primary endpoint of improved 6-month progression free survival (PFS). 7 As such, gemcitabine plus cisplatin remained the standard of care for management of BTCs in the first line setting for over 10 years. Unfortunately, the prognosis for patients with advanced BTC remained poor, prompting the need for better options. More recently, the role of immunotherapy in combination with standard chemotherapy has been evaluated in advanced BTC, including immune checkpoint inhibitors such as durvalumab and pembrolizumab. This is in line with recent changes in management of hepatocellular carcinoma, with first line options now including atezolizumab plus bevacizumab following the IMbrave150 trial, and the combination of tremelimumab plus durvalumab following the HIMALAYA trial. 8,9 As of September 2022, durvalumab in addition to chemotherapy has received US Food and Drug Administration (FDA) approval for treatment of advanced or metastatic BTC in the first-line setting. This was followed by FDA approval for pembrolizumab plus chemotherapy in 2024. This review will aim to discuss the role of durvalumab in the treatment of advanced BTC and summarize the current evidence to date. Before discussing the role of immunotherapy in BTC, it is important to understand the tumor microenvironment (TME) and how it may facilitate a response to immune checkpoint inhibition. The TME of BTC contains different cell populations, including regulatory T cells, cancer associated fi -Abstract Truncated-

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.

Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer

Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer.

The Combination of Radiation Therapy and Immunotherapy is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer

P-347 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Transarterial Chemoembolization Combined with Durvalumab or Durvalumab Plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma: EMERALD-1

APACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumours (GCT): Results from the expanded combination therapy cohort

A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.

Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration

A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer

A Real-World Study of the Efficacy and Safety of Anti-Programmed Cell Death-1 Therapy Combined with Chemotherapy or Targeted Therapy in Patients with Advanced Biliary Tract Cancer.

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study.

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers